A Phase 1 Single-dose Open Label 3-way Crossover Study To Evaluate The Bioavailability Of A Spray Dried Dispersion Solid Dose Formulation Of Pf-06260414 Relative To A Suspension Formulation Under Fasted Conditions And The Effect Of Food On The Bioavailability Of The Pf-06260414 Spray Dried Dispersion Solid Formulation In Healthy Subjects
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 01 May 2015
At a glance
- Drugs PF 626414 (Primary)
- Indications Cachexia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 27 Apr 2015 Planned End Date changed from 1 May 2015 to 1 Jul 2015 as per ClinicalTrials.gov record.
- 27 Apr 2015 Planned primary completion date changed from 1 May 2015 to 1 Jul 2015 as per ClinicalTrials.gov record.
- 27 Apr 2015 Planned initiation date changed from 1 Apr 2015 to 1 Jun 2015 as per ClinicalTrials.gov record.